Uncertainty surrounding US tariffs and global economic headwinds has tempered hiring in India's pharma and healthcare GCCs. Experts predict...

India's vaccine market is steadily recovering after the impact from Covid-19 and multinationals are back to slowly gaining traction, sugges...

At a time when the local market is assuming the centre stage of the growth strategy for Indian pharma companies, multinational drugmakers a...

While Indian companies still control almost 80% of the market in the country, the strategy of launching specialised patented product is hel...

The committee demands caution on the issue from the government and reiterates its recommendation to impose a blanket ban in FDI in brown fi...

The rejection of the Glivec patent has added to pharma MNCs’ woes after a slew of measures in the past one year.

Multi-national pharma companies have increased their focus in the country following their rapid growth in the Indian market.

To take advantage of the robust growth of the domestic pharma industry, MNCs are looking at alliances and partnerships.

The government today said multi national companies (MNCs) are campaigning against domestic pharma industry as their interests were getting ...

Imposing restrictions on FDI in the pharmaceutical sector, in the wake of MNCs acquiring domestic firms would hurt overseas investment flow...

The pharma and healthcare sectors hit headlines on account of M&As, but inbound buyouts by MNCs raised concerns over availability of low-co...

Foreign drugmakers are poised to regain the supremacy they ceded during the 1970s, thanks to their strategy of gobbling up India’s leading ...

Acquisitions to help MNCs control nearly 50% of $9.5-billion domestic retail drug market: Analysts

Acquisitions of Indian pharma companies by large multinationals has raised fears.

The Indian drug industry and public health interest groups have voiced strong concerns over the new definition of counterfeit drugs that ha...

Pharma giants like Pfizer, Novartis and Merck have seen their market capitalisation erode over the last three years, as sales started to wi...

Colleen Cheng and Angel Chen, Chinese marketing executives in their 30s, should be the ideal customers for US and European drugmakers.